Loading stock data…
$296.93-6.61 (-2.18%)
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
Ligand Pharmaceuticals Incorporated in the Healthcare sector is trading at $296.93 with a market capitalization of $5.6B. Wall Street consensus targets $344.25 (12 analysts), implying a +15.9% move over the next 12 months. The stock is currently near its 52-week high of $326.63, remaining 20.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $63.69M↑ | $51.72M↓ | $59.67M↓ | $115.46M↑ | $47.63M |
| Gross Profit | $60.48M↑ | $48.45M↓ | $56.67M↓ | $111.66M↑ | $44.72M |
| Operating Income | $8.59M↓ | $17.37M↓ | $20.04M↓ | $54.10M↑ | $9.72M |
| Net Income | $48.51M↑ | -$13.35M↓ | $44.78M↓ | $117.27M↑ | $4.85M |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA an...